Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.